Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

AITL Clinical Trial

Official title: A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Status Recruiting

Clinical Trial Summary

The prognosis of PTCL (except early stage ALK+ ALCL) is dismal. Previous study showed that single agent lenalidomide showed promising therapeutic activity in patients with relapsed or refractory PTCL. The investigators therefore design this phase II study to investigate the safety and efficacy of lenalidomide in combination with CHOP in patients with treatment-naive PTCL.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• AITL
• ALK- ALCL
• EATL
• Lymphoma, Large-Cell, Anaplastic
• Lymphoma, T-Cell, Peripheral
• Phase III-IV ALK+ ALCL
• PTCL, NOS

• NCT number: NCT04423926
• Study type: Interventional
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: Li Wang, M.D., Ph.D.
• Phone: 86 25 68306034
• Email: lilyw7878@163.com
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: June 10, 2020
• Completion date: December 31, 2024